Natus Medical (NasdaqGS:NTUS) - Share price, News & Analysis

NTUS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

NTUS Stock Overview

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide.

Rewards

Earnings are forecast to grow 58.92% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results

Natus Medical Competitors

NeuroMetrix

NasdaqCM:NURO

US$30.2m

Mettler-Toledo International

NYSE:MTD

US$28.1b

Vishay Precision Group

NYSE:VPG

US$396.8m

Shekel Brainweigh

ASX:SBW

AU$21.5m

Price History & Performance

Summary of all time highs, changes and price drops for Natus Medical
Historical stock prices
Current Share Price	US$32.91
52 Week High	US$33.93
52 Week Low	US$20.90
Beta	0.23
1 Month Change	-1.53%
3 Month Change	42.72%
1 Year Change	22.25%
3 Year Change	25.61%
5 Year Change	-4.33%
Change since IPO	127.75%

Recent News & Updates

Mar 04

Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

What underlying fundamental trends can indicate that a company might be in decline? When we see a declining return on...

Shareholder Returns

	NTUS	US Medical Equipment	US Market
7D	1.0%	0.5%	-2.7%
1Y	22.3%	-16.2%	-12.9%

Return vs Industry: NTUS exceeded the US Medical Equipment industry which returned -16.2% over the past year.

Return vs Market: NTUS exceeded the US Market which returned -12.9% over the past year.

Price Volatility

Is NTUS's price volatile compared to industry and market?
NTUS volatility
NTUS Average Weekly Movement	9.8%
Medical Equipment Industry Average Movement	10.6%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: NTUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: NTUS's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	1,400	Tom Sullivan	https://www.natus.com

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.

Natus Medical Fundamentals Summary

How do Natus Medical's earnings and revenue compare to its market cap?
NTUS fundamental statistics
Market Cap	US$1.13b
Earnings (TTM)	US$12.68m
Revenue (TTM)	US$478.30m

88.9x

P/E Ratio

2.4x

P/S Ratio

Is NTUS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTUS income statement (TTM)
Revenue	US$478.30m
Cost of Revenue	US$199.61m
Gross Profit	US$278.70m
Other Expenses	US$266.01m
Earnings	US$12.68m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0.37
Gross Margin	58.27%
Net Profit Margin	2.65%
Debt/Equity Ratio	0%

How did NTUS perform over the long term?

See historical performance and comparison

Valuation

Is Natus Medical undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

88.85x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: NTUS ($32.91) is trading above our estimate of fair value ($19.21)

Significantly Below Fair Value: NTUS is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: NTUS is poor value based on its PE Ratio (88.9x) compared to the US Medical Equipment industry average (35.2x).

PE vs Market: NTUS is poor value based on its PE Ratio (88.9x) compared to the US market (15.2x).

Price to Earnings Growth Ratio

PEG Ratio: NTUS is poor value based on its PEG Ratio (1.5x)

Price to Book Ratio

PB vs Industry: NTUS is overvalued based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (2.4x).

Future Growth

How is Natus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

3/6

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

58.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTUS's forecast earnings growth (58.9% per year) is above the savings rate (1.9%).

Earnings vs Market: NTUS's earnings (58.9% per year) are forecast to grow faster than the US market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NTUS's revenue (4.4% per year) is forecast to grow slower than the US market (7.8% per year).

High Growth Revenue: NTUS's revenue (4.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NTUS's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Natus Medical performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

9.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NTUS has a large one-off loss of $7.4M impacting its March 31 2022 financial results.

Growing Profit Margin: NTUS became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: NTUS's earnings have grown by 9.7% per year over the past 5 years.

Accelerating Growth: NTUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NTUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.5%).

Return on Equity

High ROE: NTUS's Return on Equity (2.9%) is considered low.

Financial Health

How is Natus Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: NTUS's short term assets ($286.8M) exceed its short term liabilities ($112.9M).

Long Term Liabilities: NTUS's short term assets ($286.8M) exceed its long term liabilities ($24.3M).

Debt to Equity History and Analysis

Debt Level: NTUS is debt free.

Reducing Debt: NTUS has no debt compared to 5 years ago when its debt to equity ratio was 35.5%.

Debt Coverage: NTUS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NTUS has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Natus Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTUS's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTUS has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure

CEO

Tom Sullivan (57 yo)

0.42

Tenure

US$5,167,297

Compensation

Mr. Thomas Joseph Sullivan, also known as Tom, has been the Chief Executive Officer and President of Natus Medical Incorporated since December 27, 2021 and serves as its Director. Mr. Sullivan served as Pr...

CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD5.17M) is above average for companies of similar size in the US market ($USD3.94M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: NTUS's management team is considered experienced (3.3 years average tenure).

Board Members

Experienced Board: NTUS's board of directors are considered experienced (3.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31